Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Josephson MA et al. | Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. | 2004 | Transplantation | pmid:15502727 |
Johnson MC et al. | QT prolongation and Torsades de Pointes after administration of FK506. | 1992 | Transplantation | pmid:1373538 |
van Hooff JP et al. | A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. | 2003 | Transplantation | pmid:12829890 |
Stegall MD et al. | Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | 1997 | Transplantation | pmid:9422416 |
Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
Donnadieu B et al. | Central retinal vein occlusion-associated tacrolimus after liver transplantation. | 2014 | Transplantation | pmid:25955343 |
Mourad G et al. | Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. | 2001 | Transplantation | pmid:11579299 |
Vacher-Coponat H et al. | Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. | 2006 | Transplantation | pmid:16926601 |
Ciancio G et al. | Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. | 2011 | Transplantation | pmid:22027927 |
Prud'homme GJ et al. | GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. | 2013 | Transplantation | pmid:23851932 |
Bäckman L et al. | FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. | 1994 | Transplantation | pmid:7509516 |
Tanaka M et al. | Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. | 1996 | Transplantation | pmid:8830837 |
Ekberg H et al. | The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. | 2009 | Transplantation | pmid:19424036 |
Jain A et al. | Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. | 2001 | Transplantation | pmid:11374410 |
Cherikh WS et al. | Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. | 2003 | Transplantation | pmid:14627905 |
Sommerer C et al. | Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. | 2010 | Transplantation | pmid:20463649 |
Froud T et al. | Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. | 2008 | Transplantation | pmid:19104407 |
Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
Uchikoshi F et al. | Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. | 1996 | Transplantation | pmid:8669109 |
Dieterle CD et al. | Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. | 2004 | Transplantation | pmid:15239622 |